Aliases & Classifications for Movement Disease

MalaCards integrated aliases for Movement Disease:

Name: Movement Disease 12 14
Movement Disorders 51 40 41 69
Abnormality of Movement 28


External Ids:

Disease Ontology 12 DOID:480
MeSH 41 D009069
NCIt 46 C116757
SNOMED-CT 64 60342002
UMLS 69 C0026650

Summaries for Movement Disease

MedlinePlus : 40 Imagine if parts of your body moved when you didn't want them to. If you have a movement disorder, you experience these kinds of impaired movement. Dyskinesia is abnormal uncontrolled movement and is a common symptom of many movement disorders. Tremors are a type of dyskinesia. Nerve diseases cause many movement disorders, such as Parkinson's disease. Other causes include injuries, autoimmune diseases, infections and certain medicines. Many movement disorders are inherited, which means they run in families. Treatment varies by disorder. Medicine can cure some disorders. Others get better when an underlying disease is treated. Often, however, there is no cure. In that case, the goal of treatment is to improve symptoms and relieve pain.

MalaCards based summary : Movement Disease, also known as movement disorders, is related to essential tremor and dystonia, and has symptoms including pseudobulbar signs, symptoms and sleeplessness. An important gene associated with Movement Disease is TOR1A (Torsin Family 1 Member A), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Chks in Checkpoint Regulation. The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are behavior/neurological and cellular

Related Diseases for Movement Disease

Diseases related to Movement Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 essential tremor 31.9 DRD3 FMR1 LRRK2 PRKN SLC6A3 SNCA
2 dystonia 30.9 ATP1A3 DRD2 GCH1 PANK2 PRKN SGCE
3 supranuclear palsy, progressive, 1 30.1 DRD2 LRRK2 MAPT PARK7 PRKN SLC6A3
4 stereotypic movement disorder 12.4
5 periodic limb movement disorder 12.3
6 prrt2-associated paroxysmal movement disorders 11.9
7 childhood-onset motor and cognitive regression syndrome with extrapyramidal movement disorder 11.9
8 extrapyramidal and movement disease 11.9
9 mirror movements 1 11.8
10 psychogenic movement 11.7
11 ocular motility disease 11.5
12 mental retardation, x-linked 102 11.3
13 hereditary late-onset parkinson disease 10.6 LRRK2 SNCA
14 multifocal dystonia 10.6 ATP1A3 TOR1A
15 parkinson disease 6, autosomal recessive early-onset 10.5 PARK7 PINK1
16 oromandibular dystonia 10.5 GCH1 TOR1A
17 rem sleep behavior disorder 10.5 LRRK2 SLC6A3 SNCA
18 stiff-person syndrome 10.5
19 choreatic disease 10.5
20 focal dystonia 10.5 DRD2 SGCE TOR1A
21 segawa syndrome, autosomal recessive 10.4 GCH1 TH
22 striatonigral degeneration 10.4 DRD2 SLC6A3 SNCA
23 postencephalitic parkinson disease 10.4 LRRK2 MAPT SNCA
24 cocaine abuse 10.4 DRD2 SLC6A3 SNCA
25 hereditary dystonia 10.4 GCH1 TH
26 aphasia 10.4 LRRK2 MAPT SNCA
27 muscular dystrophy, congenital, megaconial type 10.4 PINK1 PRKN
28 akinetic mutism 10.4 MAPT SLC6A3
29 perry syndrome 10.4 SLC6A3 SNCA TH
30 neurodegeneration with brain iron accumulation 10.4 FTL PANK2 SNCA
31 pathological gambling 10.4 DRD2 DRD3 SLC6A3
32 segmental dystonia 10.4 GCH1 TOR1A
33 hyperphenylalaninemia, bh4-deficient, b 10.3 GCH1 TH
34 toxic encephalopathy 10.3 SLC6A3 SNCA TH
35 leukodystrophy, hypomyelinating, 2 10.3 GCH1 HTT PANK2 TOR1A
36 cocaine dependence 10.3 DRD2 DRD3 SLC6A3
37 dystonia 1, torsion, autosomal dominant 10.3 GCH1 SGCE TH TOR1A
38 hemidystonia 10.3 ATP1A3 GCH1 SGCE SNCA TOR1A
39 personality disorder 10.3 DRD2 DRD3 SLC6A3
40 substance abuse 10.3 DRD2 DRD3 SLC6A3
41 dystonia 12 10.3 ATP1A3 GCH1 PANK2 SGCE TOR1A
42 delusional disorder 10.3 DRD2 DRD3 TH
43 gilles de la tourette syndrome 10.3 DRD2 SGCE SLC6A3
44 early-onset schizophrenia 10.3 DRD2 DRD3 TH
45 polysubstance abuse 10.2 DRD2 DRD3
46 opiate dependence 10.2 DRD2 DRD3 TH
47 substance dependence 10.2 DRD2 DRD3 SLC6A3
48 obsessive-compulsive disorder 10.2 DRD2 DRD3 SGCE SLC6A3
49 parkinson disease 10 10.2 LRRK2 PARK7 PINK1 PRKN SNCA
50 parkinson disease 2, autosomal recessive juvenile 10.2 LRRK2 PARK7 PINK1 PRKN SNCA

Graphical network of the top 20 diseases related to Movement Disease:

Diseases related to Movement Disease

Symptoms & Phenotypes for Movement Disease

UMLS symptoms related to Movement Disease:

pseudobulbar signs, symptoms, sleeplessness, myokymia, vertigo/dizziness, involuntary movements, akathisia, hyperexplexia, clumsiness, asterixis, muscle fibrillation, spasmodic torticollis, cogwheel rigidity, chronic pain, tremor, torticollis, syncope, spasm, seizures, sciatica, pain, myoclonus, muscle cramp, leg cramps, headache, dystonia, back pain, athetosis, ataxia

MGI Mouse Phenotypes related to Movement Disease:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 SLC6A3 TOR1A SNCA SGCE SLC2A1 TH
2 cellular MP:0005384 10.41 SLC6A3 TOR1A SNCA SGCE SLC2A1 TH
3 homeostasis/metabolism MP:0005376 10.39 SLC6A3 TOR1A SNCA SLC2A1 TH MAPT
4 growth/size/body region MP:0005378 10.38 TH SLC6A3 TOR1A SNCA SLC2A1 PINK1
5 mortality/aging MP:0010768 10.31 TH SLC6A3 TOR1A SNCA SLC2A1 DRD3
6 nervous system MP:0003631 10.28 SLC6A3 TOR1A SNCA SGCE SLC2A1 TH
7 cardiovascular system MP:0005385 10.26 TH SNCA SGCE HTT DRD3 PINK1
8 endocrine/exocrine gland MP:0005379 10.19 TH SLC6A3 SNCA HTT PINK1 FMR1
9 integument MP:0010771 10.09 TH SLC6A3 PRKN SNCA HTT MAPT
10 muscle MP:0005369 9.97 SLC6A3 PRKN SGCE TOR1A MAPT ATP1A3
11 no phenotypic analysis MP:0003012 9.91 TH SNCA SLC2A1 PINK1 MAPT PRKN
12 normal MP:0002873 9.81 TH SLC6A3 PRKN SNCA TOR1A HTT
13 renal/urinary system MP:0005367 9.5 SNCA DRD3 MAPT GAMT PANK2 DRD2
14 taste/olfaction MP:0005394 9.1 SLC6A3 SNCA PINK1 MAPT DRD2 HTT

Drugs & Therapeutics for Movement Disease

Drugs for Movement Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 611)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-92-7 6047
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable 120014-06-4 3152
5 Benperidol Approved, Investigational Phase 4 2062-84-2
6 bromperidol Approved, Investigational Phase 4 10457-90-6
Clozapine Approved Phase 4,Phase 3,Not Applicable 5786-21-0 2818
Fluphenazine Approved Phase 4 69-23-8 3372
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
Haloperidol Approved Phase 4,Phase 2,Not Applicable 52-86-8 3559
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
12 Perazine Approved, Investigational Phase 4 84-97-9
Perphenazine Approved Phase 4,Phase 2 58-39-9 4748
Pimozide Approved Phase 4,Phase 2 2062-78-4 16362
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 136236-51-6 3052776
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104632-26-0 119570 59868
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91374-20-8, 91374-21-9 5095 497540
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 768-94-5 2130
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 89594 942
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
Clonidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 4205-90-7 2803
Galantamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 357-70-0 9651
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-00-4, 41372-20-7 6005
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28860-95-9 38101 34359
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130929-57-6 5281081
Midodrine Approved Phase 4,Phase 1,Not Applicable 42794-76-3, 133163-28-7 4195
Menthol Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
Armodafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 112111-43-0
Modafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
37 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68291-97-4 5734
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
Selegiline Approved, Investigational, Vet_approved Phase 4,Not Applicable 14611-51-9 5195 26757
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 525-66-6 4946
Trimethobenzamide Approved, Investigational Phase 4,Phase 1 138-56-7 5577
Methylphenidate Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 20748-11-2, 113-45-1 4158
Topiramate Approved Phase 4,Phase 3,Phase 2,Not Applicable 97240-79-4 5284627
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
49 Benserazide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 322-35-0
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602

Interventional clinical trials:

(show top 50) (show all 2896)

# Name Status NCT ID Phase Drugs
1 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
2 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
3 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
5 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
6 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
7 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
8 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
9 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
10 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
11 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
12 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
13 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
14 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
15 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
16 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
17 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
18 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
19 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
20 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4 placebo;rasagiline
21 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
22 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
23 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
24 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
25 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
26 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
27 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
28 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
29 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
30 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
31 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
32 Investigation of the Use of Remote Presence Robots in Delivery of Neuromodulation Completed NCT01283633 Phase 4
33 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
34 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4 Methylphenidate (MPD);Placebo
35 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed NCT00208091 Phase 4 Botulinum toxin, type B
36 Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
37 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease Completed NCT01662414 Phase 4
38 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4 Tigan®;Placebo
39 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed NCT00640159 Phase 4 Zelapar
40 Stalevo in Early Wearing-Off Patients Completed NCT00125567 Phase 4 Stalevo (levodopa/carbidopa/entacapone);Levodopa/carbidopa
41 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
42 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
43 A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis Completed NCT00644800 Phase 4 Ziprasidone
44 A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
45 A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs Completed NCT00649064 Phase 4 Ziprasidone
46 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
47 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
48 Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults Completed NCT02191579 Phase 4 Topiramate
49 EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) Completed NCT00230568 Phase 4 Aricept
50 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine

Search NIH Clinical Center for Movement Disease

Cochrane evidence based reviews: movement disorders

Genetic Tests for Movement Disease

Genetic tests related to Movement Disease:

# Genetic test Affiliating Genes
1 Abnormality of Movement 28

Anatomical Context for Movement Disease

MalaCards organs/tissues related to Movement Disease:


Publications for Movement Disease

Articles related to Movement Disease:

# Title Authors Year
Muscle co-activity tuning in Parkinsonian hand movement: disease-specific changes at behavioral and cerebral level. ( 26300761 )

Variations for Movement Disease

Copy number variations for Movement Disease from CNVD:

# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 262562 X 37500000 47300000 Deletion MAOA Movement disorder
2 262566 X 37500000 47300000 Deletion MAOB Movement disorder

Expression for Movement Disease

Search GEO for disease gene expression data for Movement Disease.

Pathways for Movement Disease

GO Terms for Movement Disease

Cellular components related to Movement Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.91 ATP1A3 LRRK2 MAPT SLC6A3 SNCA TH
2 membrane raft GO:0045121 9.88 LRRK2 PARK7 SLC2A1 SLC6A3
3 cytoplasmic vesicle membrane GO:0030659 9.83 HTT SNCA TH TOR1A
4 perikaryon GO:0043204 9.8 DRD2 FMR1 LRRK2 TH
5 dendrite GO:0030425 9.8 DRD2 FMR1 HTT LRRK2 MAPT SGCE
6 sarcolemma GO:0042383 9.79 ATP1A3 SGCE SLC2A1
7 synaptic vesicle GO:0008021 9.78 LRRK2 SNCA TH TOR1A
8 cell body GO:0044297 9.77 MAPT PARK7 PINK1
9 mitochondrial intermembrane space GO:0005758 9.77 PANK2 PARK7 PINK1
10 terminal bouton GO:0043195 9.74 LRRK2 SNCA TH
11 axon terminus GO:0043679 9.73 DRD2 FMR1 SNCA
12 postsynapse GO:0098794 9.71 FMR1 LRRK2 SNCA
13 presynapse GO:0098793 9.71 FMR1 PARK7 PRKN SLC6A3
14 neuron projection GO:0043005 9.7 FMR1 LRRK2 PARK7 PRKN SLC6A3 TH
15 inclusion body GO:0016234 9.63 HTT LRRK2 SNCA
16 autolysosome GO:0044754 9.58 FTL LRRK2
17 Lewy body GO:0097413 9.51 PINK1 PRKN
18 growth cone GO:0030426 9.43 FMR1 LRRK2 MAPT PINK1 SNCA TOR1A
19 axon GO:0030424 9.36 ATP1A3 DRD2 FMR1 HTT LRRK2 MAPT
20 cytoplasm GO:0005737 10.25 ATP1A3 FMR1 GAMT GCH1 HTT LRRK2
21 cytosol GO:0005829 10.24 FMR1 FTL GAMT GCH1 HTT LRRK2
22 cell projection GO:0042995 10.09 DRD3 FMR1 LRRK2 MAPT SGCE TOR1A
23 perinuclear region of cytoplasm GO:0048471 10.02 FMR1 HTT PARK7 PINK1 PRKN SNCA
24 synapse GO:0045202 10 ATP1A3 FMR1 LRRK2 SNCA TOR1A

Biological processes related to Movement Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.98 PARK7 PINK1 PRKN SNCA
2 response to oxidative stress GO:0006979 9.98 LRRK2 PINK1 PRKN TOR1A
3 response to ethanol GO:0045471 9.95 DRD2 DRD3 SLC6A3 TH
4 cellular response to oxidative stress GO:0034599 9.92 LRRK2 PARK7 PINK1 SNCA
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 PARK7 PINK1 SNCA
6 excitatory postsynaptic potential GO:0060079 9.91 DRD2 LRRK2 SNCA
7 mitochondrion organization GO:0007005 9.91 LRRK2 PARK7 PINK1 PRKN
8 cerebral cortex development GO:0021987 9.9 ATP1A3 SLC2A1 TH
9 memory GO:0007613 9.9 ATP1A3 MAPT TH
10 learning GO:0007612 9.9 DRD3 PRKN TH
11 regulation of autophagy GO:0010506 9.89 LRRK2 MAPT PRKN
12 negative regulation of protein phosphorylation GO:0001933 9.88 LRRK2 PARK7 PRKN SNCA
13 visual learning GO:0008542 9.87 ATP1A3 DRD2 DRD3
14 protein destabilization GO:0031648 9.87 HTT PRKN SNCA
15 response to nicotine GO:0035094 9.86 DRD2 SLC6A3 TH
16 adult locomotory behavior GO:0008344 9.86 ATP1A3 PARK7 PRKN SNCA
17 negative regulation of neuron death GO:1901215 9.85 LRRK2 PARK7 PRKN SNCA
18 locomotory behavior GO:0007626 9.83 DRD2 DRD3 PRKN SLC6A3 TH
19 negative regulation of blood pressure GO:0045776 9.82 DRD2 DRD3 GCH1
20 response to amphetamine GO:0001975 9.82 DRD2 DRD3 TH
21 response to cocaine GO:0042220 9.81 DRD2 DRD3 SLC6A3 SNCA
22 regulation of reactive oxygen species metabolic process GO:2000377 9.8 PINK1 PRKN SNCA
23 behavioral response to cocaine GO:0048148 9.78 DRD2 DRD3 SNCA
24 regulation of neurotransmitter secretion GO:0046928 9.77 FMR1 PRKN SNCA
25 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.77 LRRK2 PARK7 PRKN
26 regulation of protein ubiquitination GO:0031396 9.76 PINK1 PRKN
27 startle response GO:0001964 9.76 DRD2 PRKN
28 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.76 LRRK2 PARK7
29 regulation of mitochondrial membrane potential GO:0051881 9.76 PANK2 PARK7 PINK1 PRKN
30 microglial cell activation GO:0001774 9.75 MAPT SNCA
31 positive regulation of mitochondrial fission GO:0090141 9.75 PINK1 PRKN
32 cellular response to dopamine GO:1903351 9.75 LRRK2 PRKN
33 neurotransmitter biosynthetic process GO:0042136 9.75 SLC6A3 TH
34 regulation of mitochondrion organization GO:0010821 9.75 PINK1 PRKN
35 negative regulation of voltage-gated calcium channel activity GO:1901386 9.75 DRD2 FMR1
36 negative regulation of autophagosome assembly GO:1902902 9.75 LRRK2 PINK1
37 prepulse inhibition GO:0060134 9.75 DRD2 DRD3 SLC6A3
38 negative regulation of macroautophagy GO:0016242 9.74 LRRK2 PINK1
39 supramolecular fiber organization GO:0097435 9.74 MAPT SNCA
40 positive regulation of renal sodium excretion GO:0035815 9.74 DRD2 DRD3
41 negative regulation of oxidative stress-induced neuron death GO:1903204 9.74 PARK7 PINK1
42 striatum development GO:0021756 9.74 DRD2 LRRK2
43 synaptic vesicle transport GO:0048489 9.74 SNCA TOR1A
44 G-protein coupled receptor internalization GO:0002031 9.74 DRD2 DRD3
45 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.73 DRD2 DRD3
46 regulation of dopamine metabolic process GO:0042053 9.73 PRKN SLC6A3
47 adenohypophysis development GO:0021984 9.72 DRD2 SLC6A3
48 regulation of mitochondrial fission GO:0090140 9.72 LRRK2 MAPT
49 intracellular distribution of mitochondria GO:0048312 9.72 LRRK2 MAPT
50 cellular response to toxic substance GO:0097237 9.71 PINK1 PRKN

Molecular functions related to Movement Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 9.8 FMR1 LRRK2 MAPT SNCA
2 enzyme binding GO:0019899 9.77 MAPT PARK7 PRKN SNCA TH
3 drug binding GO:0008144 9.65 DRD2 DRD3 SLC6A3
4 identical protein binding GO:0042802 9.65 DRD2 FMR1 FTL HTT LRRK2 MAPT
5 ubiquitin-specific protease binding GO:1990381 9.56 PARK7 PRKN
6 phospholipase binding GO:0043274 9.55 PRKN SNCA
7 dynactin binding GO:0034452 9.54 HTT MAPT
8 ferric iron binding GO:0008199 9.51 FTL TH
9 tubulin binding GO:0015631 9.5 LRRK2 MAPT PRKN
10 D1 dopamine receptor binding GO:0031748 9.46 ATP1A3 DRD3
11 kinase binding GO:0019900 9.46 HTT PARK7 PRKN SLC2A1
12 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3
13 cuprous ion binding GO:1903136 9.4 PARK7 SNCA
14 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3
15 dopamine binding GO:0035240 8.92 DRD2 DRD3 SLC6A3 TH
16 protein homodimerization activity GO:0042803 10 DRD2 FMR1 GCH1 LRRK2 MAPT PARK7

Sources for Movement Disease

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
51 Novoseek
54 OMIM via Orphanet
58 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....